Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Arcus Biosciences (RCUS) Stock Price & Analysis
423 Followers
RCUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.95 - $25.47
Previous Close$14.28
Volume489.20K
Average Volume (3M)715.50K
Market Cap
$1.30B
Enterprise Value$303.81M
Total Cash (Recent Filing)$995.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 01, 2024EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding90,953,011
10 Day Avg. Volume1,119,913
30 Day Avg. Volume715,499
Standard Deviation0.23
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.22
Price to Sales (P/S)12.71
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit2.60
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$34.14Price Target Upside139.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Arcus Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsArcus' HIF-2alpha inhibitor, casdatifan, has shown promising results in its Phase 1/1b expansion study for clear cell renal cell carcinoma, potentially positioning it as a strong contender in the market.
Competitive PositionArcus' EDGE-Gastric trial demonstrated a median progression-free survival of 12.9 months, significantly outperforming current benchmarks and showing strong potential for success in upper GI cancers.
Market PotentialArcus is likely to face minimal competition in the anti-Claudin 18.2 antibody space due to high toxicity rates in competing programs, giving it a strategic advantage.
Bears Say
Clinical Data51% of patients experienced Grade 3+ neutropenia events compared to the target of less than 20%.
Clinical Trial IssuesMerck discontinued its coformulation arm of the Phase 3, KeyVibe-010, trial studying Merck's anti-TIGIT, vibostolimab, in combo with pembro due to a higher discontinuation rate of adjuvant therapy in the coformulation arm vs pembro alone.
Investor SentimentInvestors are cautious on Arcus, where doubts over their potential have weighed despite good progress advancing a pipeline of late-stage oncology assets.
---
Ownership Overview
41.04% Insiders
17.65% Mutual Funds
15.76% Other Institutional Investors
25.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $12.95 and its highest was $25.47 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Currently, no data Available
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on May 08, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$1.01 by $0.96.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -$1.12.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 90,953,010 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$1.01. Following the earnings report the stock price went up 5.832%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Among the largest hedge funds holding Arcus Biosciences Inc’s share is Woodline Partners LP. It holds Arcus Biosciences Inc’s shares valued at 54M.
---
Arcus Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.14 (139.08% Upside)
$34.14 (139.08% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.76%
12-Months-Change
Fundamentals
Return on Equity
-35.35%
Trailing 12-Months
Asset Growth
3.11%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
---
RCUS Company Deck
---
RCUS Earnings Call
Q1 2024
0:00 / 0:00
---
RCUS Stock 12 Month Forecast
Average Price Target
$34.14
▲(139.08% Upside)
Technical Analysis
Best Analysts Covering RCUS
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
+0.41%
assigned a buy rating 3 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +0.41% per trade.
---